164 related articles for article (PubMed ID: 31700732)
1. B-cell Prolymphocytic Leukemia: Case Report and Challenges on a Diagnostic and Therapeutic Forefront.
Bindra BS; Kaur H; Portillo S; Emiloju O; Garcia de de Jesus K
Cureus; 2019 Sep; 11(9):e5629. PubMed ID: 31700732
[TBL] [Abstract][Full Text] [Related]
2. Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax.
Siddiqui MT; Price A; Ferrajoli A; Borthakur G
Leuk Res Rep; 2021; 16():100266. PubMed ID: 34692401
[TBL] [Abstract][Full Text] [Related]
3. A patient with white blood cell counts more than a million: A diagnostic and therapeutic challenge.
Figueroa-Jiménez LA; Cabrera-Márquez AL; Báez-Díaz L; Cáceres-Perkins W
Bisturi (S Juan); 2016; 2016():12-16. PubMed ID: 29238632
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
5. De novo chronic lymphocytic leukemia/prolymphocytic leukemia or B-cell prolymphocytic leukemia? The importance of integrating clinico-morphological and immunophenotypic findings in distinguishing chronic lymphoproliferative diseases with circulating phase.
Chowdhury Z; Khonglah Y; Sarma S; Kalita P
Autops Case Rep; 2021; 11():e2020196. PubMed ID: 34277479
[TBL] [Abstract][Full Text] [Related]
6. Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion.
Coelho H; Badior M; Melo T
Case Rep Hematol; 2017; 2017():8563218. PubMed ID: 28819574
[TBL] [Abstract][Full Text] [Related]
7. How I treat prolymphocytic leukemia.
Dearden C
Blood; 2012 Jul; 120(3):538-51. PubMed ID: 22649104
[TBL] [Abstract][Full Text] [Related]
8. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract][Full Text] [Related]
9. B-cell prolymphocytic leukemia with P53 abnormalities successfully treated with bendamustine and rituximab: a report of three cases.
Wang A; Guo W; Damiani D; Sumbly V; Goyal G; Du Z; Bai O
Transl Cancer Res; 2023 Jul; 12(7):1873-1882. PubMed ID: 37588745
[TBL] [Abstract][Full Text] [Related]
10. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
12. An Unusual Case of Prolymphocytic Leukemia Transformation in a Patient With Chronic Lymphocytic Leukemia.
Bell S; Lattanzio N; Braham J; Campdesuner V; Abdelal Q; Vartanov A; Pelayo M
J Investig Med High Impact Case Rep; 2021; 9():2324709621990767. PubMed ID: 33533282
[TBL] [Abstract][Full Text] [Related]
13. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
[TBL] [Abstract][Full Text] [Related]
14. Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia.
Brothers J; Castillo DR; Jeon WJ; Joung B; Linhares Y
Hematology; 2023 Dec; 28(1):2237342. PubMed ID: 37485976
[No Abstract] [Full Text] [Related]
15. B- and T-cell prolymphocytic leukemia: antibody approaches.
Dearden C
Hematology Am Soc Hematol Educ Program; 2012; 2012():645-51. PubMed ID: 23233647
[TBL] [Abstract][Full Text] [Related]
16. Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy.
Sakhdari A; Tang G; Ginsberg LE; Hirsch-Ginsberg CF; Bueso-Ramos CE; Medeiros LJ; Miranda RN
Case Rep Pathol; 2019; 2019():4915086. PubMed ID: 30941227
[TBL] [Abstract][Full Text] [Related]
17. [Chronic lymphocytic leukemia: update on pathophysiology and management].
Suzumiya J
Rinsho Ketsueki; 2018; 59(5):511-520. PubMed ID: 29877241
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
Chow KU; Kim SZ; von Neuhoff N; Schlegelberger B; Stilgenbauer S; Wunderle L; Cordes HJ; Bergmann L
Eur J Haematol; 2011 Nov; 87(5):426-33. PubMed ID: 21749447
[TBL] [Abstract][Full Text] [Related]
19.
Menakuru SR; Roepke J; Siddiqui S
J Hematol; 2023 Apr; 12(2):82-86. PubMed ID: 37187496
[TBL] [Abstract][Full Text] [Related]
20. Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia.
Oka S; Ono K; Nohgawa M
Invest New Drugs; 2020 Oct; 38(5):1598-1600. PubMed ID: 31965420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
